Evidence map›Paper›PMID 35928014›Full record

ArticleFrontiers in neuroscience2022

Convolutional Neural Networks for Classification of T2DM Cognitive Impairment Based on Whole Brain Structural Features.

Xin Tan, Jinjian Wu, Xiaomeng Ma, Shangyu Kang, Xiaomei Yue, Yawen Rao, Yifan Li, Haoming Huang, Yuna Chen, Wenjiao Lyu and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Xin TanFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Jinjian WuFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Xiaomeng MaFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Shangyu KangFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Xiaomei YueFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yawen RaoFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yifan LiFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Haoming HuangMedical Imaging Center, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Yuna ChenMedical Imaging Center, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Wenjiao LyuFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Chunhong QinMedical Imaging Center, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Mingrui LiFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yue FengFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yi LiangMedical Imaging Center, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Shijun QiuMedical Imaging Center, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Guangzhou University of Chinese Medicine · CNFirst Affiliated Hospital of Guangzhou University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Cognitive impairment is generally found in individuals with type 2 diabetes mellitus (T2DM). Although they may not have visible symptoms of cognitive impairment in the early stages of the disorder, they are considered to be at high risk. Therefore, the classification of these patients is important for preventing the progression of cognitive impairment. Methods: In this study, a convolutional neural network was used to construct a model for classifying 107 T2DM patients with and without cognitive impairment based on T1-weighted structural MRI. The Montreal cognitive assessment score served as an index of the cognitive status of the patients. Results: The classifier could identify T2DM-related cognitive decline with a classification accuracy of 84.85% and achieved an area under the curve of 92.65%. Conclusions: The model can help clinicians analyze and predict cognitive impairment in patients and enable early treatment.

Indexed as

classificationcognitive impairmentconvolutional neural networksMRItype 2 diabetes mellitus

Identifiers

PMID35928014
PMCPMC9344913
OpenAlexW4286220080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.